Management of Poststroke Hyperglycemia: Results of the TEXAIS Randomized Clinical Trial.

"Disclosures The authors declare no competing interests for the TEXAIS trial (Treatment With Exenatide in Acute Ischemic Stroke). Dr Grimley declares travel support from Boehringer Ingleheim. Dr Meretoja declares research funding support from Monash University. Dr Davis declares research funding support from Medtronic, Amgen, CSL Behring, AstraZeneca, and Boehringer Ingelheim. Dr Ekinci is a consultant in Eli Lilly, Australia and reports research funding support from Eli Lilly, Australia, Amgen, Boehringer Ingelheim, and Bayer. Dr Thijs is a consultant in Bayer, Boehringer Ingelheim, Medtronic, and Novo Nordisk. Dr Lee-Archer declares research funding support from Clifford Craig Foundation. The other authors report no conflicts."

"Sources of Funding The TEXAIS (Treatment With Exenatide in Acute Ischemic Stroke) was supported by research grant 1126070 from the National Health and Medical Research Council of Australia. The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. Material support from Medtronic in the use of Medtronic iPro2 Professional Continuous Glucose Monitors."

"REGISTRATION:: URL: www.australianclinicaltrials.gov.au; Unique identifier: ACTRN12617000409370. URL: https://www.clinicaltrials.gov; Unique identifier: NCT03287076."